Hypercalcemia due to all trans retinoic acid in the treatment of acute promyelocytic leukemia potentiated by voriconazole.
All-trans-retinoic acid (ATRA) is a new and effective treatment of acute promyelocytic leukemia. It has many side-effects, including the retinoic acid syndrome and Sweet's syndrome. There have been only nine cases of hypercalcemia associated with ATRA described in the literature. We discuss a case of hypercalcemia, which we believe was due to inhibition of cytochrome P450 function by voriconizole when used concomitantly with ATRA.
Bennett
Matthew T
MT
Department of Medicine, University of British Columbia, Vancouver, BC, Canada. matthebe@interchange.ubc.ca
Sirrs
Sandra
S
Yeung
Janice K
JK
Smith
Clayton A
CA
D000328:Adult; D000935:Antifungal Agents / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D011743:Pyrimidines / Q000009:adverse effects*; D016896:Treatment Outcome; D014212:Tretinoin / Q000009:adverse effects*; D014230:Triazoles / Q000009:adverse effects*; D065819:Voriconazole
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D011743:Pyrimidines; D014230:Triazoles; D014212:Tretinoin; D065819:Voriconazole